Clinical Trials on Diabetic Nephropathy: A Cross-Sectional Analysis

Sergio Modafferi · Markus Ries · Vittorio Calabrese · Claus. P. Schmitt · Peter Nawroth · Stefan Kopf · Verena Peters

Received: November 9, 2018 / Published online: January 7, 2019 © The Author(s) 2019

ABSTRACT

Introduction: Treatment options and decisions are often based on the results of clinical trials. We have evaluated the public availability of results from completed, registered phase III clinical trials on diabetic nephropathy and current treatment options.

Methods: This was a cross-sectional analysis in which STrengthening the Reporting of OBservational studies in Epidemiology criteria were applied for design and analysis. In June 2017, 34 completed phase III clinical trials on diabetic nephropathy in the ClinicalTrials.gov registry were identified and matched to publications in the ClinicalTrials.gov registry and to those in the PubMed and Google Scholar databases. If no publication was identified, the principal investigator was contacted. The ratio of published and non-published studies was calculated. Various parameters, including study design, drugs, and comparators provided, were analyzed.

Results: Drugs/supplements belonged to 26 different categories of medications, with the main ones being angiotensin-converting enzyme inhibitors, angiotensin-II receptors blockers, and dipeptidyl-peptidase-4-inhibitors. Among the trials completed before 2016 \((n = 32)\), 22 \((69\%)\) were published, and ten \((31\%)\) remained unpublished. Thus, data on 11 different interventions and more than 1000 patients remained undisclosed. Mean time to publication was 26.5 months, which is longer than the time constrictions imposed by the U.S. Food and Drug Administration Amendments Act. Most trials only showed weak effects on micro- and macroalbuminuria, with an absolute risk reduction of 1.0 and 0.3\%, respectively, and the number needed to treat varied between 91 and 333, without any relevant effect on end-stage-renal disease by intensive glucose-lowering treatment. Comparison of the results,

Enhanced Digital Features To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.7410617.
however, was difficult since study design, interventions, and the renal outcome parameters vary greatly between the studies.

**Conclusion:** Despite the financial and human resources involved and the relevance for therapeutic guidelines and clinical decisions, about one-third of phase III clinical trials on diabetic nephropathy remain unpublished. Interventions used in published trials showed a low efficacy on renal outcome.

**Funding:** Deutsche Forschungsgemeinschaft (DFG); SFB 1118.

**Keywords:** ACE inhibitors; Angiotensin-II receptors; ClinicalTrials.gov; Diabetes mellitus; Diabetic nephropathy; Dipeptidyl-peptidase-4-inhibitors; Phase III clinical trials

**INTRODUCTION**

The ever-increasing global prevalence of diabetes mellitus, which was estimated to affect over 415 million people worldwide in 2017 [1], is giving rise to serious concern among healthcare providers. Diabetic nephropathy (DN) is a major complication associated with both type 1 and type 2 diabetes (T1DM and T2DM, respectively) and is the leading cause of end-stage renal disease (ESRD) [2]. DN follows distinct phases, wherein glomerular hyperfiltration is followed by a relentless decline in renal function, typically occurring over a 15- to 20-year period [3]. The development of ESRD requires the patient to receive dialysis or undergo renal transplantation, two procedures which are associated with excess morbidity and mortality [4]. The current standard treatment regimen for patients with T2DM involves lifestyle modifications and medical treatment targeted against the fundamental dysregulation of glucose and hypertension [3, 5], but this strategy is unable to affect the underlying pathophysiology of the DN. Although the results of many studies indicate a correlation between the degree of hyperglycemia and progression of DN, diabetic patients receiving intensive glycemic control therapy continue to develop DN. Hyperglycemia can in fact induce modifications in gene expressions which persist even after normoglycemia is restored through a process known as metabolic memory [6]. In a recent study, the risk of development of kidney complications was correlated with a specific cluster of diabetic patients with insulin-resistance, leading the authors to suggest that glucose-lowering therapy is not the optimum management strategy for preventing this complication. Hence, there is a need to focus on new therapeutic targets and initiate treatments at an early stage in order to prevent complications [7]. Treatment options and decisions are often based on the results of clinical trials that meet the highest standards of scientific rigor and ethical oversight [8]. The specific aim of phase III clinical trials is to confirm results obtained in previous experimental trials; as such, phase III clinical trials must test experimental study drugs or treatment in larger populations in order to confirm the effectiveness and safety of use of the drug(s) under study (https://www.fda.gov/). To realize the benefits of a clinical trial, the results must be shared quickly after the study has concluded [9]. However, timely dissemination of clinical trial results continues to be a serious issue. Since favorable results of intervention by drugs are twofold more likely to be published than negative or unfavorable results [10], the efficacy of a drug may be overestimated by the medical community, and trials may be unnecessarily repeated. Beyond the impact on treatment decisions, however, there is an explicit ethical obligation to publish towards study participants, as mandated by the Declaration of Helsinki. Therefore, the nonpublication of trial outcome data is against ethical obligations that investigators have towards study participants. In this context, the aim of our study was to assess the public availability of results of phase III clinical trials on DN. Since treatment options and decisions are often based on clinical trials, knowledge on current therapies and their outcome is of utmost importance.

**METHODS**

The analysis was performed according to STROBE (STrengthening the Reporting of
Observational studies in Epidemiology) criteria. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

**Clinical Trials Search**

For the cross-sectional analysis, we searched the Clinical Trials.gov registry of clinical trials in June 2017 for clinical trials on DN, with the added restriction of only completed phase III trials. The search was performed by entering the keywords “diabetic nephropathy” and “diabetic renal disease” in the ClinicalTrials.gov search engine. Data on studies obtained from the database were organized in a spreadsheet for analysis. The data available on ClinicalTrials.gov included National Clinical Trial (NCT) number, study title, study description, study design, eligibility criteria, enrollment, arm and interventions, outcome measures, primary completion date, and availability of study results. Following the evaluation of these parameters, we excluded studies that did not meet the following exclusion criteria: no diabetic patients investigated and/or intervention not relevant for diabetic kidney disease (DKD).

**Publication Search**

A trial was considered to have been published when the results were present in the ClinicalTrials.gov registry or when a journal had published a peer-reviewed manuscript online or in print that included primary or secondary outcome data from the trial in question. When the ClinicalTrials.gov registry did not provide results or links to publications in peer-reviewed journals, we searched the PubMed or/and Google Scholar databases for articles using the study identification number (NCT), the study title, and other study identification numbers. When no published results were found on these latter two databases, the principal investigators (PIs) or sponsors were contacted by email and asked to provide either an article with the study results, which we might have missed, or the reason for the failure to publish the results. Feedback on the missing publications and available data on unpublished clinical trials were analyzed. Clinical trial results that could not be obtained by the preceding described procedure were assessed as unpublished.

**Time to Publication**

Time to publication refers to the period of time between the primary completion date of the clinical trial and the date of publication of the results either on the ClinicalTrials.gov registry or in peer-reviewed journals. The calculation of the time to publication was performed in accordance with the Food and Drug Administration Amendments Act of 2007 (FDAAA) which requires the publication of results within 1 year after completion of the trial [11] and, therefore, our analysis regarded only studies completed before 2016.

**Absolute Risk Reduction Analysis and Patient Number Needed to Treat**

The absolute risk reduction (AAR) is the change in the risk of an outcome of a given treatment or activity in relation to a comparison treatment or activity. The number needed to treat (NNT) corresponds to the inverse of the absolute risk reduction.

**Statistical Analysis**

The following continuous or categorical variables were analyzed: NCT number, study title, gender, age, study phase, study type, study design, condition, intervention, recruitment status, primary completion date and completion date, availability of study results, publication date, time to publication, sponsor, and funding source. Standard methods of descriptive statistics were applied. Two-sided p values 0.05 were considered to be statistically significant.
RESULTS

Publication of Clinical Trials

A total of 49 completed phase III clinical trials were identified from the search of the ClinicalTrials.gov registry in June 2017. Of these studies, 15 were excluded from subsequent analysis since they did not include diabetic patients or any intervention for DKD (Fig. 1). Of the remaining 34 studies, 22 were published and 12 were unpublished. The results of seven studies were recorded in the ClinicalTrials.gov registry, with a direct link provided between these studies and publications in peer-reviewed journals of 11 other studies. Publications on two studies were identified by searching the PubMed/Google Scholar databases, and in two cases, published manuscripts were sent directly to the authors by the PIs. Regarding the unpublished studies, we received answers from six of the 12 PIs or sponsors contacted. Of these, three asserted they were in the process of finalizing the paper or submitting it to journals; two stated that the reasons for failure to publish were “adverse effect” of the testing drug (one case) and “no funds” (one case); and one declared that the results were only available on the sponsor’s website. The FDAAA requires the results of clinical trials to be published within 1 year after the completion of the study; thus, in accordance with the FDAAA, in our analysis of publications we considered only those trials completed before 2016 (n = 32). Of these, 22 studies (69%) had been published, with a mean time to publication of 26.5 (median 23.5, standard deviation [SD] 16.5) months for published studies completed before 2016 and for which the primary dates were available (n = 18). Thus, only 33% of the studies analyzed met all FDAAA criteria (Fig. 2).

Characteristics of Clinical Trials

The interventions tested were either compared to a placebo control group (20 studies; 59%), to another intervention or to standard care (11 studies; 32%), or to no intervention (3 studies; 9%). Most of the studies (30/34) included renal parameters as primary or secondary outcomes. Overall, 16 different renal parameters were measured to study the effect of interventions on the renal system. Of these, proteinuria and glomerular filtration rate (GFR) were main renal parameters analyzed—in 23 and 14 clinical trials, respectively; progression to ESRD was tested in only three studies (Fig. 3). None of the 34 studies performed a gender-specific analysis; allocation of participants in groups was predominantly randomized (88%). The interventions tested included 26 different categories, with the most represented drug classes being angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-II receptor blockers (ARBs). Data on 11 different interventions, 19 renal outcomes, and more than 1000 patients remained undisclosed (Table 1).
Interventions Efficacy on Renal Outcomes

The effects of interventions on the renal outcomes described in the 22 published studies are summarized in Table 2 [12–32]. Two-thirds (77%) of the published studies versus 25% of the non-published studies compared the interventions to a placebo control group. The most common interventions were ARBs (7 studies) and/or ACEi (5 studies). The cohort size in these studies varied between 22 and 11,140 patients. Whereas most studies included solely patients with T2DM, two studies included patients solely with T1DM [17, 18], and two studies included patients with either T1DM or T2DM [24, 33]. No improvement on renal outcome parameters, such as proteinuria/albuminuria and/or GFR, was reported for most medications [12, 14, 16, 19, 20, 24, 26–30, 32]. Proteinuria/albuminuria was improved only by the addition of ARB treatment to the standard therapeutic regimen [13, 17] or by the addition of vitamin D₃ to the standard therapy (study NCT00552409). The addition of sodium–glucose cotransporter 2 inhibitors reduced the urine albumin-to-creatinine ratio (UACR) but not the GFR, but only when added to the standard therapy [31]. Medication with ACEi and a diuretic in addition to standard therapy [25] reduced the risk of DN.

Relative and Absolute Risk Reduction

Two published clinical trials obtained significant risk reduction of renal events. Patel et al. described a relative risk reduction of 21% for a combined endpoint (total renal events) [25], and Haller et al. described a relative risk reduction of 16% for new onset of microalbuminuria [26]. For these two trials, absolute risk reduction (ARR) and number needed to treat (NNT) were calculated (Table 3). Combined intervention with perindopril + indapamide in addition to current therapy [25] reduced the relative risk of nephropathy and of new microalbuminuria by 18 and 21%, respectively. This means that 159 patients need to be treated to prevent new onset or worsening nephropathy in one patient (ARR 0.6%), and 25 patients need to be treated to prevent new onset of microalbuminuria in one
patient (ARR 4%). In Patel et al.’s study [26], the absolute risk for new microalbuminuria was reduced by 2% with olmesartan; thus, 63 patients need to be treated to avoid the development of new microalbuminuria in one patient. An effect on ESRD was not found in either of these studies.

DISCUSSION

Since treatment options and decisions are often based on the results of clinical trials, knowledge of the outcome of these studies is of great importance. In our analysis, 31% of the completed phase III clinical trials on DN remained unpublished, which is in line with previous findings on phase III clinical trials on other diseases [34–36]. The high number of undisclosed clinical trials may lead to an underestimation of the relevance of DN in the medical literature and thereby hinder a correct risk–benefit assessment of a certain intervention. It is well known that trials showing a benefit of a drug or device have a much greater chance of full publication than trials showing no benefit [37] due to commercial interest and publication strategy of papers since Editors prefer articles that guarantee citations [10]. In addition to publication bias, adverse events are...
| NCT          | Intervention                | Intervention category | Question/aim                                                                                     | Cohort                  | Completion date |
|-------------|-----------------------------|-----------------------|--------------------------------------------------------------------------------------------------|-------------------------|-----------------|
| NCT00362960| Olmesartan ARB             |                       | Effect of olmesartan vs. losartan on proteinuria, renal function, and inflammatory markers       | 300 diabetic patients with DN | 09-2004         |
| NCT00782847| DiaNeal: behavior-modifying support program | Behavioral | Effect on deterioration of kidney function and on glycemic control                               | 125 diabetic patients with DN | 01-2007         |
| NCT00556465| N-Acetylcysteine Antioxidant |                       | Effect on proteinuria, blood pressure, serum creatinine, glomerular filtration rate, C-reactive protein | 60 diabetic patients with DN | 06-2007         |
| NCT00297401| Ruboxis-taurine PKCi        |                       | Effects of PKC inhibition on renal and peripheral hemodynamic function                           | 20 T1DM patients with evidence of early DN | 11-2007         |
| NCT00663949| Captopril + pentoxifylline  | ACEi + TNFa blocker   | Effect of captopril vs. combination of captopril and pentoxifylline on reducing proteinuria     | 70 diabetic patients with DN | 01-2008         |
| NCT00507494| Pioglitazone TZD            |                       | Effect on proteinuria and renal function of kidney transplant recipients with T2DM              | Not provided            | 09-2009         |
| NCT00765830| Vildagliptin DPP-4i         |                       | Safety and tolerability of vildagliptin and effect on renal insufficiency                       | 349 diabetic patients with renal insufficiency | 04-2011         |
| NCT01219959| Dianeal, extraneal, nutrineal (D–E–N) | Peritoneal dialysis solution | Effect of D-E-N vs. DiaNe only on glycosylated hemoglobin, glycemic control medication usage, hypoglycemic events, nutritional status, quality of life | 71 diabetic CAPD patients | 07-2011         |
| NCT01875341| NCPAP                       | Respiratory device    | Effect of NCPAP vs. NCPAP sub-therapeutic treatment on blood pressure, renin, and aldosterone, sympathetic activity | 16 diabetic patients with DN | 02-2015         |
| NCT01847313| Liraglutide GLP-1           |                       | Effect on DN by reducing inflammation in the kidney                                             | 20 diabetic patients with diabetic kidney disease | 11-2015         |
often poorly described. Some studies fail to report the incidences of severe, serious, and fatal adverse events, such as in cancer drug trials [38]. The failure to publish negative results and the underestimation of adverse events lead to an accumulation of literature favoring the benefits of treatments [10].

Further, we found that the time to publication of results was longer than that recommended by FDAAA, with a mean time to publication of 26.5 months compared to the 12 months required by the FDAAA. The effect is a delay in reporting therapeutic strategies. A comparison of results from the various studies, however, remains difficult since study design and the renal outcome parameters vary greatly between the studies.

Overall, the interventions reported in each study, which were aimed at improving renal outcomes, showed low efficacy. The initial clinical evidence of renal involvement in patients with T2DM is usually the appearance of microalbuminuria, which has been defined as a urine albumin excretion rate (UACR) of 30–299 mg/24 h [39]. Patients with diabetes mellitus and microalbuminuria are at high risk of developing overt progressive DN [12]. Urinary albumin concentrations in the upper normal range have been reported to predict both cardiovascular and renal events in both high- and low-risk populations. For these and other reasons, some authors suggest the treatment of urinary albumin excretion as a continuous variable [40]. Proteinuria was measured in many of the clinical trials analyzed (14/34 published trials), indicating that it is used as an important predictor of renal outcome when evaluating DN (Fig. 3). A decline in eGFR was also broadly used to assess the effectiveness of interventions, but only a few studies investigated the risk of ESRD because it requires long-term trials. The measurement of urine protein excretion and eGFR varied greatly among the studies, complicating a reliable comparison of the outcomes [41]. This comparison is further complicated by the fact that current clinical recommendations for the treatment of DN are based on results that in the initial study investigated another primary endpoint (usually glucose therapy), with renal outcome evaluated only secondarily. The

| Table 1 continued |
| NCT | Intervention category | Question/aim | Cohort | Completion date |
| NCT00393152 | ACEi + ARB or valsartan | Effect of benazepril + valsartan combination vs. benazepril or valsartan alone on microalbuminuria and cardiovascular events | 613 diabetic patients | 09-2016 |
| NCT02807974 | ACEi + ARB or valsartan | Safety of administration and effect on blood pressure and albuminuria | 51 diabetic patients with albuminuria | 03-2017 |
| NCT03003652 | ACEi + ARB or valsartan | Safety of administration and effect on blood pressure and albuminuria | 51 diabetic patients with albuminuria | 03-2017 |

ACEi: Angiotensin-converting enzyme inhibitor; ARB: angiotensin-II receptor blocker; DN: diabetic nephropathy; DPP-4i: dipeptidyl peptidase 4 inhibitor; GLP-1: glucagon-like peptide 1; GLP-1R: glucagon-like peptide 1 receptor; LPS: lipopolysaccharide; NCPAP: nasal continuous positive airway pressure; NCT: ClinicalTrials.gov registry number; PkCγ: protein kinase C gamma; TZD: thiazolidinediones; T2DM: type 2 diabetes mellitus; TNFa: tumor necrosis factor α; T2D: type 2 diabetes.
Table 2  Characteristics of the completed phase III clinical trials on diabetic nephropathy that were published ($n = 22$): effects on renal outcomes

| NCT        | Intervention                                                                 | Cohort                                                | Effect                                                                                                           | Publication                                      |
|------------|------------------------------------------------------------------------------|-------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|
| NCT00130208 | Sulodexide (glycosaminoglycan) vs. Placebo                                   | 1056 DM2 patients with DN                             | Sulodexide failed to decrease urine albumin excretion                                                        | Lewis EJ et al. Am J Kidney Dis. (2011)          |
| NCT00141453 | Olmertasan (ARB) in addition to standard therapy (ACEi) vs. Placebo          | 577 Asian DM2 patients with DN                        | Olmesartan reduced blood pressure and proteinuria but had no effect on primary composite outcome of doubling of serum creatinine, end stage renal disease and death | Imai E, Chan JCN et al. Diabetologia (2011)       |
| NCT00340678 | Losartan (ARB) vs. Placebo                                                   | 169 American Indians DM2 with normoalbuminuria or microalbuminuria | No effect on GFR (primary outcome)                                                                             | Well EJ et al. Diabetes (2013)                   |
| NCT00354341 | Epoetin beta vs. Placebo                                                     | 172 DM patients with CKD                              | No effect on GFR and no change in urine protein excretion                                                    | Ritz E et al. Am J Kidney Dis. (2007)            |
| NCT00136188 | NG-monomethyl-L-arginine (L-NMMA) (blockade of NO synthases)                  | 84 DM2 patients with normal renal function            | NOS inhibition with L-NMMA provoked an increase in UACR                                                      | Ott C et al. Diabetes (2011)                     |
| NCT00274118 | Telmisartan (ARB) vs. Enalapril (ACEi)                                       | 250 DM2 patients with early nephropathy               | Telmisartan was not inferior to Enalapril in preventing the progression of renal dysfunction, measured as the decline in the GFR. No differences in change of GFR, serum creatinine, urinary albumin excretion and rates of ESRD between the two drugs | Barnett AH et al. N Engl J Med (2004)            |
| NCT00738660 | Telmisartan (ARB) + Ramipril (ACEi) (crossover)                              | 30 DM1 patients with micro or macroalbuminuria        | Telmisartan and Ramipril had complimentary significant effect on lowering of the BP, but similar beneficial effect on the nocturnal dipping was not observed possibly due to inappropriate chronotherapy. Reduction in albumin excretion rate. | Anantharaman R et al. Indian J Med Res (2011)     |
| NCT00552409 | Vitamin D3 in addition to standard therapy (ACEi or ARB) vs. Placebo         | 22 DM patients with early kidney disease.              | Mean UACR on treatment was 17% lower among participants assigned to Vit D3 compared to participants assigned to placebo | ClinicalTrials.gov                               |
| NCT00941552 | Pulsatile intravenous insulin therapy (PIVIT) in addition to Diabetes Control and Complications Trial (DCCT) intensive therapy (IT) regimen. | 90 type DM 1 patients with nephropathy               | PIVIT added to IT slowed the decline of creatinine clearance showing to reduce the progression of diabetic nephropathy. The effect appears independent of ACE inhibitor therapy, blood pressure, or glycemic control. No decrease in urine protein excretion | Dailey GE et al. Metabolism (2000)               |
| NCT01092390 | Long-chain n-3 polyunsaturated fatty acid (n-3 PUFA) vs. Placebo             | 29 DM2 patients                                       | n-3 PUFA had significant effects on urine NGAL, excretion compared to placebo. No significant effect on urine albumin excretion, on serum markers of kidney function and on GFR. In subgroup analyses, there were significant decreases in 24-h urinary excretion of albumin, NGAL, LFABP, and NAG among participants taking medications that block the renin-angiotensin-aldosterone system (RAAS) | Miller III ER et al. Diabetes Care (2013)         |
| NCT01204528 | Paracalcitrol vs. Placebo                                                    | Two groups of patients (n=72) 1) CKD 2)CKD+DM.       | No renal outcomes                                                                                              | Lundwall K et al. Am J Nephrol (2015)            |
| Study ID | Intervention | Participants | Results |
|----------|--------------|--------------|---------|
| NCT01419912 | Soy milk vs. cow milk | 25 DM2 patients with DN | Soy milk had no significant effects on inflammatory markers (tumor necrosis factor-a, interleukin-6, high-sensitivity C-reactive protein) |
| NCT01835678 | Linagliptin (DPP-4i) vs. Placebo | 62 DM2 patients | Linagliptin prevented upregulation of basal NO activity; UACR increased in the placebo group but not in the linagliptin group. No significant effect on renal plasma flow, GFR and intrarenal hemodynamics; no change in tubular markers; linagliptin reduced hs-CRP but not MCP-1 |
| NCT00317915 | Irbesartan (ARB) vs. Placebo | 590 DM2 patients with microalbuminuria | Endothelial dysfunction and inflammation markers (vWF, Plasma sVCAM-1, sICAM-1, Interleukin-6) are novel predictors of progression to DN in DM2 and persistent microalbuminuria, independently of traditional risk factor |
| NCT01831193 | Curcumin vs. Placebo | 101 Mexican patients with non-diabetic or diabetic proteinuric CKD (51% diabetic) | Curcumin did not improve proteinuria and eGFR; in plasma enhanced antioxidant capacity in subjects with diabetic proteinuric CKD. No effect was observed on the antioxidant enzymes activities or Nrf2 activation |
| NCT00145925 | Perindopril (ACEi) + Indapamide (Diuretic) in addition to current therapy vs. Placebo | 11140 DM2 patients | Intervention did reduce the risk of nephropathy (development of macroalbuminuria, doubling of serum creatinine, need for renal replacement therapy, or death due to renal disease). Reduction of systolic and diastolic blood pressure |
| NCT00185159 | Olmesartan (ARB) vs. Placebo | 4447 DM2 normoalbuminuric patients | Olmesartan was associated with a delayed onset of microalbuminuria. No change in eGFR and serum creatinine. ESRD did not develop in any patient |
| NCT00157586 | Manidipine (CCB)/Delapril (ACEi) vs. Delapril alone vs. Placebo | 380 hypertensive type 2 diabetics with albuminuria | Combined treatment failed to slow GFR decline and progression to micro/macroalbuminuria or regression to normoalbuminuria |
| NCT0157586 | Linagliptin (DPP-4i) added to preexisting therapy vs. Placebo | 133 DM2 patients with severe chronic renal impairment | Average eGFR values did not decrease by a clinically meaningful degree with either linagliptin or placebo |
| NCT01316094 | Ipragliflozin (SGLT2i) vs. Placebo | 165 DM2 patients, Japanese with mild or moderate renal impairment (RI) | No renal outcomes |
| NCT01087502 | Linagliptin (DPP-4i) + Glimepiride (sulfonylurea) vs. Placebo | 235 DM2 patients with moderate or severe renal impairment | eGFR remained stable throughout the 52 weeks in both groups |
| NCT01164501 | Empagliflozin (SGLT2i) in addition to standard therapy vs. Placebo | 741 DM2 patients with micro/macroalbuminuria | Empagliflozin reduced UACR by a clinically meaningful amount; this effect was largely independent of the known metabolic or systemic haemodynamic effects of this drug class; no significant change in eGFR |

**CCB** Calcium channel blocker, **CKD** chronic kidney disease, **eGFR** estimated glomerular filtration rate, **ESRD** end stage renal disease, **hs-CRP** high-sensitive C-reactive protein, **LFABP** liver fatty acid–binding protein, **MCP-1** monocyte chemoattractant protein-1, **NAG** N-acetyl b-D-glucosaminidase, **NGAL** neutrophil gelatinase-associated lipocalin, **NOS** NO synthase, **SGLT2i** sodium-glucose cotransporter-2 inhibitor, **sICAM-1** soluble intercellular adhesion molecule-1, **sVCAM** soluble vascular cell adhesion molecule-1, **T2DM** type 1 diabetes mellitus, **UACR** urine albumin-to-creatinine ratio, **vWF** von Willebrand factor
DCCT/EDIC study showed that only 24 of 1441 patients developed ESRD after more than 25 years of observation. The ARR was only 1.7% with a NNT of 74 patients due to intensive glucose therapy in patients with T1DM [42]; in patients with T2DM similar results were shown. The mega-trials (ACCORD, ADVANCED, VADT, and UKPDS) only showed weak effects on micro- and macroalbuminuria, with an ARR of 1.0 and 0.3%, respectively, and an NNT of between 91 and 333 patients, without any relevant effect on ESRD by intensive glucose-lowering treatment [43]. In addition, empagliflozin seems to be a new treatment option for DN, but the main effects shown to date are on surrogate parameters, such as creatinine doubling (ARR 1%, NNT 20) and worsening of albuminuria (ARR 5%, NNT 20), while ESRD occurred with an ARR of 0.3% and NNT of 310 [44]. Almost two-thirds of all trials were placebo-controlled, with a higher percentage of placebo-controlled trials in published studies than in unpublished trials (77 vs. 25%, respectively). Placebo-controlled trials produce strong evidence of the effectiveness of a new intervention, limited only by the statistical uncertainty of the outcome [45]. However, knowledge about the relative efficacies between various drugs is also needed for decision-making in clinical practice. In our analysis, only one study [27] compared an intervention to both placebo and another drug(s).

The most represented drug classes in all trials were ACEi and ARBs. Angiotensin-II receptor blockers are renoprotective in hypertensive azotemic patients with T2DM, but their efficacy in early DKD is uncertain. Findings support the current recommendation that inhibitors of the renin–angiotensin–aldosterone system should not be used for primary prevention of DN in normotensive normoalbuminuric persons with diabetes. However, these medications seem to mitigate the progression of DKD when used after the onset of microalbuminuria. ACEi has demonstrated efficacy in reducing cardiovascular risk [27] and, in combination with diuretics, and also shown to correlate with a reduced risk of developing microalbuminuria [25]. However, their effects on preventing DN progression have been less clear, and they have failed to reduce the decline in GFR [21, 23]. A growing body of evidence indicates that the decline in GFR might occur irrespectively of the progression of albuminuria in non-proteinuric DN phenotypes [46]. Altogether, these data call for an early intervention that targets potential mediators of renal dysfunction other than proteinuria to prevent or slow GFR decline already at the stage of normoalbuminuria. In this regard, the role of reactive metabolites [47] and inflammation in the progression to DN is gaining attention. The mechanisms involved are little understood, with evidence of increased inflammatory cytokines (monocyte chemoattractant protein 1 [MCP-1], human tumor necrosis factor alpha [TNF-α]), and mononuclear infiltrates in the glomeruli and tubulointerstitium that would contribute to the progression of DN [45]. Endothelial dysfunction and inflammation markers (von Willebrand factor [vWF], plasma soluble vascular cell adhesion molecule-1 [SVCAM-1], soluble intercellular adhesion molecule-1 [sICAM-1] and interleukin-6 [IL-6])

Table 3 Risk reduction of renal events in two completed phase III clinical trials on diabetic nephropathy

| Studies | Relative risk reduction (%) | NNT (needed to treat) | ARR (absolute risk reduction) (%) |
|---------|-----------------------------|-----------------------|-------------------------------|
| Perindopril + indapamide (Patel et al. 2007) [25] | | | |
| Total renal events | 21 | 22 | 5 |
| New or worsening nephropathy | 18 | 159 | 0.6 |
| New microalbuminuria | | | |
| All deaths | 14 | 89 | 1 |
| Olmesartan (Haller H et al. 2011) [26] | | | |
| New microalbuminuria | 16 | 63 | 2 |

a Values of NNT (needed to treat) and ARR (absolute risk reduction) were calculated from data in publications
b New or worsening nephropathy + new microalbuminuria
c Development of macroalbuminuria; doubling of serum creatinine to a level of at least 200 μmol/L; need for renal replacement therapy; or death due to renal disease

DCCT/EDIC study showed that only 24 of 1441 patients developed ESRD after more than 25 years of observation. The ARR was only 1.7% with a NNT of 74 patients due to intensive glucose therapy in patients with T1DM [42]; in patients with T2DM similar results were shown. The mega-trials (ACCORD, ADVANCED, VADT, and UKPDS) only showed weak effects on micro- and macroalbuminuria, with an ARR of 1.0 and 0.3%, respectively, and an NNT of between 91 and 333 patients, without any relevant effect on ESRD by intensive glucose-lowering treatment [43]. In addition, empagliflozin seems to be a new treatment option for DN, but the main effects shown to date are on surrogate parameters, such as creatinine doubling (ARR 1%, NNT 20) and worsening of albuminuria (ARR 5%, NNT 20), while ESRD occurred with an ARR of 0.3% and NNT of 310 [44]. Almost two-thirds of all trials were placebo-controlled, with a higher percentage of placebo-controlled trials in published studies than in unpublished trials (77 vs. 25%, respectively). Placebo-controlled trials produce strong evidence of the effectiveness of a new intervention, limited only by the statistical uncertainty of the outcome [45]. However, knowledge about the relative efficacies between various drugs is also needed for decision-making in clinical practice. In our analysis, only one study [27] compared an intervention to both placebo and another drug(s).

The most represented drug classes in all trials were ACEi and ARBs. Angiotensin-II receptor blockers are renoprotective in hypertensive azotemic patients with T2DM, but their efficacy in early DKD is uncertain. Findings support the current recommendation that inhibitors of the renin–angiotensin–aldosterone system should not be used for primary prevention of DN in normotensive normoalbuminuric persons with diabetes. However, these medications seem to mitigate the progression of DKD when used after the onset of microalbuminuria. ACEi has demonstrated efficacy in reducing cardiovascular risk [27] and, in combination with diuretics, and also shown to correlate with a reduced risk of developing microalbuminuria [25]. However, their effects on preventing DN progression have been less clear, and they have failed to reduce the decline in GFR [21, 23]. A growing body of evidence indicates that the decline in GFR might occur irrespectively of the progression of albuminuria in non-proteinuric DN phenotypes [46]. Altogether, these data call for an early intervention that targets potential mediators of renal dysfunction other than proteinuria to prevent or slow GFR decline already at the stage of normoalbuminuria. In this regard, the role of reactive metabolites [47] and inflammation in the progression to DN is gaining attention. The mechanisms involved are little understood, with evidence of increased inflammatory cytokines (monocyte chemoattractant protein 1 [MCP-1], human tumor necrosis factor alpha [TNF-α]), and mononuclear infiltrates in the glomeruli and tubulointerstitium that would contribute to the progression of DN [45]. Endothelial dysfunction and inflammation markers (von Willebrand factor [vWF], plasma soluble vascular cell adhesion molecule-1 [SVCAM-1], soluble intercellular adhesion molecule-1 [sICAM-1] and interleukin-6 [IL-6]).
have been found to be correlated to DN onset in patients with T2DM and microalbuminuria, independently of traditional risk factors [19]. Clinical trials included in our analysis showed poor effects on inflammatory markers. Soy milk showed no significant effect on inflammation [TNF-α, IL-6 and C-reactive protein (CRP)] compared to cow milk [21], while linagliptin, a dipeptidyl peptidase-4 inhibitor, reduced CRP but not MCP-1 [22]. Further, two studies testing the effect of ARBs and liraglutide on kidney inflammation, remained unpublished (Table 2). Curcumin and long-chain –3 polyunsaturated fatty acids are examples of new interventions, as an alternative to RAAS blockade. Unfortunately, in two studies these supplements were not able to reduce proteinuria and to affect GFR [15, 20]. Conversely, vitamin D and its analogs, which activate the vitamin D receptor, were able to reduce proteinuria, inflammation, and glomerulosclerosis in animal models of DKD [48]. One small trial investigating the effect of vitamin D₃ in addition to standard therapy in 22 DM patients with early kidney disease, obtained a 17% reduction of mean UACR (ClinicalTrials.gov; NCT00552409). Pentoxifylline (phosphodiesterase inhibitor), ruboxis-taurine (protein kinase C inhibitor), and N-acetylcysteine (antioxidant) are promising molecules that showed renoprotective effect in a mouse model and in small trials on humans [48]. The data and outcomes from patients treated with these experimental drugs are as yet not available for assessment due to a delay or failure to publish (Table 1).

This analysis has some limitations. Since ClinicalTrials.gov is considered the most relevant clinical trial registry, we did not investigate other databases. In addition, the investigation of a clinical trial registry implies that only registered trials were included in our analysis. In order to prevent classifying a trial as unpublished, we conducted an exhaustive literature search in two major databases (i.e., PubMed and Google Scholar) with multiple search terms and contacted investigators or sponsors. This analysis assumes that the entries provided in the ClinicalTrials.gov registry are accurate and complete as mandated by the FDAAA. Our data define the current publication bias in phase III clinical trials investigating DN. We hope that the publication efforts will increase over time.

CONCLUSION

The need for a better publication discipline of clinical trials is obvious based on our study which found that data on 11 different interventions and more than 1000 patients remained undisclosed. Transparency in clinical research has the potential to improve patient care and prevent patients from being exposed to redundant research. The outcome of the phase III clinical trials included in our study was quite limited, and the need for new approaches to prevent or slow the progression of DN is obvious. Several mechanisms underlying DN pathophysiology have been elucidated, which opens new frontiers for the development of specific DKD therapies. Experimental therapies targeting inflammatory, oxidant, or pro-fibrotic pathways activated during DKD are currently under investigation in phase II and III clinical trials [48].

ACKNOWLEDGEMENTS

Funding. This work and the associated article processing charges were supported by the Deutsche Forschungsgemeinschaft (DFG; SFB 1118). All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Authorship Contributions. Sergio Modafferi, Markus Ries, Verena Peters, Vittorio Calabrese, Claus Peter Schmitt, Peter Nawroth, and Stefan Kopf contributed to this article. Sergio Modafferi, Markus Ries, and Verena Peters were
involved in planning this article. Vittorio Calabrese, Claus Peter Schmitt, Peter Nawroth, and Stefan Kopf were involved in interpretation of literature, and in drafting and critically revising the manuscript.

**Disclosures.** Sergio Modafferi, Markus Ries, Verena Peters, Vittorio Calabrese, Claus P Schmitt, Peter Nawroth, and Stefan Kopf have nothing to disclose.

**Compliance with Ethics Guidelines.** This article is a review of previously published work and does not present any new previously unpublished studies with human or animal subjects performed by the any of the authors.

**Data Availability.** The datasets during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Open Access.** This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any non-commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**REFERENCES**

1. Ogurtsova K, da Rocha Fernandes JD, Huang Y et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50.

2. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305:2532–9.

3. Magee C, Grieve DJ, Watson CJ, Brazil DP. Diabetic nephropathy: a tangled web to unweave. Cardiovasc Drugs Ther. 2017;31:579–92.

4. Saran R, Li Y, Robinson B, et al. US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2015;66:S1–305.

5. Chan GC, Tang SC. Diabetic nephropathy: landmark clinical trials and tribulations. Nephrol Dial Transplant. 2016;31:359–68.

6. Tonna S, El-Osta A, Cooper ME, Tikellis C. Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. Nat Rev Nephrol. 2010;6:332–41.

7. Ahlqvist E, Storm P, Karajamaki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6:361–9.

8. Guyatt GH, Haynes RB, Jaeschke RZ, et al. Users’ guides to the medical literature: 25. Evidence-based medicine: principles for applying the Users’ Guides to patient care. Evidence-Based Medicine Working Group. JAMA. 2000;284:1290–6.

9. Hudson KL, Lauer MS, Collins FS. Toward a new era of trust and transparency in clinical trials. JAMA. 2016;316:1353–4.

10. Johnson RT, Dickersin K. Publication bias against negative results from clinical trials: three of the seven deadly sins. Nat Clin Pract Neurol. 2007;3:590–1.

11. Zarin DA, Tse T, Williams RJ, Carr S. Trial reporting in ClinicalTrials.gov—the final rule. N Engl J Med. 2016;375:1998–2004.

12. Lewis EJ, Lewis JB, Greene T, et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis. 2011;58:729–36.

13. Imai E, Chan JC, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54:2978–86.

14. Weil EJ, Fufaa G, Jones LL, et al. Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes. 2013;62:3224–31.

15. Ott C, Schneider MP, Delles C, Schlaich MP, Schmieder RE. Reduction in basal nitric oxide activity causes albuminuria. Diabetes. 2011;60:572–6.

16. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952–61.
17. Anantharaman R, Bhansali A, Bhadada SK, et al. A pilot study on the effect of telmisartan and ramipril on 24 h blood pressure profile and dipping pattern in type 1 diabetes patients with nephropathy. Indian J Med Res. 2011;134:658–63.

18. Dailey GE, Boden GH, Creech RH, et al. Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy. Metabolism. 2000;49:1491–5.

19. Miller ER 3rd, Juraschek SP, Anderson CA et al. The effects of n-3 long-chain polyunsaturated fatty acid supplementation on biomarkers of kidney injury in adults with diabetes: results of the GO-FISH trial. Diabetes Care. 2013;36:1462–9.

20. Lundwall K, Jorneskog G, Jacobson SH, Spaak J. Paricalcitol, microvascular and endothelial function in non-diabetic chronic kidney disease: a randomized trial. Am J Nephrol. 2015;42:265–73.

21. Miraghajani MS, Esmaillzadeh A, Najafabadi MM, Mirlohi M, Azadbakht L. Soy milk consumption, inflammation, coagulation, and oxidative stress among type 2 diabetic patients with nephropathy. Diabetes Care. 2012;35:1981–5.

22. Ott C, Kistner I, Keller M, et al. Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial. Diabetologia. 2016;59:2579–87.

23. Persson F, Rossing P, Hovind P, et al. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. Scand J Clin Lab Investig. 2008;68:731–8.

24. Jimenez-Osorio AS, Garcia-Nino WR, Gonzalez-Reyes S, et al. The effect of dietary supplementation with curcumin on redox status and Nrf2 activation in patients with nondiabetic or diabetic proteinuric chronic kidney disease: a pilot study. J Ren Nutr. 2016;26:237–44.

25. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–40.

26. Haller H, Ito S, Izzo JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907–17.

27. Ruggenenti P, Lauria G, Iliev IP, et al. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension. 2011;58:776–83.

28. McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2013;36:237–44.

29. Kashiwagi A, Takahashi H, Ishikawa H, et al. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study. Diabetes Obes Metab. 2015;17:152–60.

30. Laakso M, Rosenstock J, Groop PH, et al. Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial. Diabetes Care. 2015;38:e15–7.

31. Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 2016;59:1860–70.

32. Ritz E, Laville M, Bilous RW, et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis. 2007;49:194–207.

33. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis. 1999;34:795–808.

34. Lampert A, Hoffmann GF, Ries M. Ten years after the International Committee of Medical Journal Editors’ Clinical Trial Registration Initiative, one quarter of phase 3 pediatric epilepsy clinical trials still remain unpublished: a cross sectional analysis. PLoS ONE. 2016;11:e0144973.

35. Mechler K, Hoffmann GF, Dittmann RW, Ries M. Defining the hidden evidence in autism research. Forty per cent of rigorously designed clinical trials remain unpublished—a cross-sectional analysis. Int J Methods Psychiatr Res. 2017;26(4). doi: https://doi.org/10.1002/mpr.1546.

36. Breil T, Boettcher M, Hoffmann GF, Ries M. Publication status of completed registered studies in paediatric appendicitis: a cross-sectional analysis. BMJ Open. 2018;8:e021684.
37. Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results Follow-up of applications submitted to two institutional review boards. JAMA. 1992;267:374–8.

38. Gyawali B, Shimokata T, Honda K, Ando Y. Reporting harms more transparently in trials of cancer drugs. BMJ. 2018;363:k4383.

39. Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2016;5:49–56.

40. Ritz E, Viberti GC, Ruilope LM, et al. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia. 2010;53:49–57.

41. Seegmiller JC, Burns BE, Schinstock CA, Lieske JC, Larson TS. Discordance between iothalamate and iohexol urinary clearances. Am J Kidney Dis. 2016;67:49–55.

42. de Boer IH, Sun W, Cleary PA, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011;365:2366–76.

43. Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5:431–7.

44. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–34.

45. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med. 2000;133:455–63.

46. Montero RM, Covic A, Gnudi L, Goldsmith D. Diabetic nephropathy: what does the future hold? Int Urol Nephrol. 2016;48:99–113.

47. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058–70.

48. Lacava V, Pellicano V, Ferrajolo C, et al. Novel avenues for treating diabetic nephropathy: new investigational drugs. Expert Opin Investig Drugs. 2017;26:445–62.